Ahmed Ismail, MD retweetledi
Proud of our residents & med students presenting at national & local conferences!
Advancing knowledge. Inspiring innovation. Shaping the future of medicine.
#MedEd #Research #FutureOfMedicine @EVMSedu
English
Ahmed Ismail, MD
249 posts
Ahmed Ismail, MD
@A_Ismail_MD
IM PGY-1 @EVMSedu @ODU | Former Research Fellow @ONealCancerUAB & @NUFeinbergMed 🇺🇸 | MD @CairoUniv 🇪🇬
Norfolk, VA Katılım Nisan 2011
468 Takip Edilen1.4K Takipçiler
Great work from future oncologist and scientist 👏 👏
Ahmed Ismail, MD@A_Ismail_MD
I had the pleasure of presenting my work at the AACR Annual Meeting 2026 and connecting with colleagues interested in hematology/oncology. Grateful for the opportunity to share my research and learn from leaders across the field.
English
I had the pleasure of presenting my work at the AACR Annual Meeting 2026 and connecting with colleagues interested in hematology/oncology.
Grateful for the opportunity to share my research and learn from leaders across the field.
English
@A_Ismail_MD إيه الحلاوة دي يا فرير 😍😍♥️♥️
So proud ❤️❤️❤️❤️
العربية
@Dan_Batlle @ardemp @CellCellPress @NUFeinbergMed @NU_Nephrology Congratulations, Dr. Batlle! Happy Holidays! 🎉
English
Nice way to end the year being part of this paper in Cell showing that PIEZO2 is an essential regulator of renin by Rose Hill and a strong group of scientists including Nobel Prize winner @ardemp.
cell.com/cell/fulltext/…
@CellCellPress @NUFeinbergMed @NU_Nephrology
English
Mechanical thrombectomy alone or with IV thrombolysis in Tandem lesions?
@svinsociety
#SVINAnnualMeeting #SVIN
English
English
I am happy to share that our paper on evaluating HER2 in solid tumors has been accepted in @OncJournal.
Thank you @ADesaiMD @Jani_Chinmay for your mentorship and guidance!
Chinmay Jani@Jani_Chinmay
Check out our recent analysis @OncJournal under mentorship of @ADesaiMD of 653 solid tumors evaluating HER2 by IHC, CNV & mutational profiling. 📊 Results: •IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg •CN amplification: 3.1% (75% IHC3+) •Pathogenic ERBB2 mutations: 3.1% (only 5% IHC3+) 🔑 ERBB2-mut tumors rarely show IHC3+/CN amp → highlights need for comprehensive genomic testing. 💡 In the era of pan-tumor T-DXd approval, integrating genomic + phenotypic data can refine patient selection & advance precision oncology. @ONealCancerUAB @MehmetAkce2 @YanisBoumberMD @BasselElRayesMD @SylvesterCancer @HemOncMiami @carisls
English
Ahmed Ismail, MD retweetledi
📢 New in @FrontOncology by @ADesaiMD, @A_Ismail_MD & @YanisBoumberMD:
HER2-altered #NSCLC: from🔬 to therapeutics 🎯
frontiersin.org/journals/oncol…
🤝 Love it!! But…can HER2 keep dancing when resistance cuts the music? 🎹
#OncoAlertAF @OncoAlert @_SEOM @gecp_org @Lung_Cancers @LungCancerRx
English
A new chapter begins: Day 1 of orientation at @EVMSMedicine ✅ Grateful and excited for the journey ahead.
English
Ahmed Ismail, MD retweetledi
English
@A_Ismail_MD Congratulations Ya basha, Wish you best of luck.
Can you please DM me, I am in Rva, would love to chat with you.
English
@A_Ismail_MD @EVMSMedicine Good luck 👍 So happy for you ♥️
English
@ADesaiMD @FrontOncology @ONealCancerUAB Thank you, Dr. Desai!
Just started my orientation today. I am so excited!
English
@A_Ismail_MD @FrontOncology @ONealCancerUAB Great work @A_Ismail_MD! Hope residency is off to a great start!
English
I am so happy to see our review published in @FrontOncology with my amazing mentors at @ONealCancerUAB 🌟
#OncoTwitter #Oncology #CancerResearch #LungCancer #NSCLC
doi.org/10.3389/fonc.2…
Aakash Desai, MD, MPH, FASCO@ADesaiMD
🚨 Just published! @FrontOncology Our review on HER2-altered #NSCLC — from biology 🧬 & testing to latest therapies 🔗 bit.ly/HER2NSCLC 🔑 #biomarker testing: tissue and #ctDNA 💥 ADCs & TKIs: T-DXd, zongertinib, A166, ARX788 📈 Future: combo trials & next-gen agents With @A_Ismail_MD @YanisBoumberMD @OncoAlert @oncodaily @LungCancerRx @OncBrothers @HemOncFellows @HendriksLizza
English